Therapeutic interventions for Netherton syndrome

Expert Review of Dermatology

Volumn 7, Issue 4, 2012, Pages 319-321

  Xiang, Nicola N ^a   Di, Wei Li ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

gene therapy; LEKTI; Netherton syndrome; pimecrolimus

Indexed keywords

ALPHA 1 ANTITRYPSIN; CALCIPOTRIOL; COMPLEMENTARY DNA; IMMUNOGLOBULIN G; KALLIKREIN; PIMECROLIMUS; PLACEBO; PROTEIN LEKT1; SERINE PROTEINASE INHIBITOR; TACROLIMUS; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); ENZYME INHIBITION; EPIDERMOLYSIS BULLOSA DYSTROPHICA; EX VIVO GENE TRANSFER; GENE; GENE MUTATION; GENE THERAPY; HUMAN; NETHERTON DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; SKIN IRRITATION; SPINK5 GENE; VIRAL GENE DELIVERY SYSTEM;

EID: 84866641602     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/edm.12.27     Document Type: Review

References (20)

1. Chavanas S, Bodemer C, Rochat A et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet. 25(2), 141-142 (2000).
2. Descargues P, Deraison C, Prost C et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin-and chymotrypsin-like hyperactivity in Netherton syndrome. J. Invest. Dermatol. 126(7), 1622-1632 (2006).
3. Borgoño CA, Michael IP, Komatsu N et al. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J. Biol. Chem. 282(6), 3640-3652 (2007).
4. Oji V, Beljan G, Beier K, Traupe H, Luger TA. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br. J. Dermatol. 153(5), 1067-1068 (2005).
5. Saif GB, Al-Khenaizan S. Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings. Int. J. Dermatol. 46(3), 290-294 (2007).
6. Allen A, Siegfried E, Silverman R et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch. Dermatol. 137(6), 747-750 (2001).
7. Frishman WH, Brosnan BD, Grossman M, Dasgupta D, Sun AD. Adverse dermatologic effects of cardiovascular drug therapy: part I. Cardiol. Rev. 10(4), 230-246 (2002).
8. Renner ED, Hartl D, Rylaarsdam S et al. Comèl-Netherton syndrome defined as primary immunodeficiency. J. Allergy Clin. Immunol. 124(3), 536-543 (2009).
9. Godic A, Dragos V. Successful treatment of Netherton's syndrome with topical calcipotriol. Eur. J. Dermatol. 14(2), 115-117 (2004).
10. Descargues P, Deraison C, Bonnart C et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat. Genet. 37(1), 56-65 (2005).
11. Ishida-Yamamoto A, Deraison C, Bonnart C et al. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. J. Invest. Dermatol. 124(2), 360-366 (2005).
12. Deraison C, Bonnart C, Lopez F et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol. Biol. Cell 18(9), 3607-3619 (2007).
13. Sales KU, Masedunskas A, Bey AL et al. Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. Nat. Genet. 42(8), 676-683 (2010).
14. Mazereeuw-Hautier J, Cope J, Ong C, Green A, Hovnanian A, Harper JI. Topical recombinant α1-antitrypsin: a potential treatment for Netherton syndrome? Arch. Dermatol. 142(3), 396-398 (2006).
15. Fortugno P, Bresciani A, Paolini C et al. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis. J. Invest. Dermatol. 131(11), 2223-2232 (2011).
16. Komatsu N, Saijoh K, Jayakumar A et al. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J. Invest. Dermatol. 128(5), 1148-1159 (2008).
17. Di WL, Larcher F, Semenova E et al. Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. Mol. Ther. 19(2), 408-416 (2011).
18. Roedl D, Oji V, Buters JT, Behrendt H, Braun-Falco M. rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients. J. Dermatol. Sci. 61(3), 194-198 (2011).
19. Mavilio F, Pellegrini G, Ferrari S et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med. 12(12), 1397-1402 (2006).
20. Wagner JE, Ishida-Yamamoto A, McGrath JA et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N. Engl. J. Med. 363(7), 629-639 (2010).